ArriVent BioPharma Inc. (AVBP) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, ArriVent BioPharma Inc. (NASDAQ: AVBP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $14.87 (-6.77% 1D, market cap $786.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AVBP ranks #872 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AVBP carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HELP (Helus Pharma Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $782.5M) and COLL (Collegium Pharmaceutical Inc.) posts a C- grade (59/100 RQD, P/E 12.4x, ROIC 85.0%, cap $782.3M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
Per AVBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001868279), ArriVent BioPharma Inc. generated $0 in revenue, -$166.3M in net income, and -$160.6M in free cash flow against $333.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 14% of 52W Range • RSI-14 at 36.9 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While AVBP currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.49) and Max Pain ($15.61) forces dealer call-delta covering toward $37.62.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
ArriVent BioPharma Inc. (AVBP) dropped -6.77% to $14.87, trading at 14% of its 52-week range ($11.36 – $35.83). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance Singapore report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
TradingView report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
Fierce Biotech report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
Morningstar report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $18 to $30.
ArriVent BioPharma (NASDAQ:AVBP) presented Phase I data for ARR-217, its CDH17-targeting antibody-drug conjugate, or ADC, in heavily pretreated metastatic colorectal cancer patients during a virtual webinar following an
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AVBP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AVBP. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, ArriVent BioPharma Inc. (AVBP) ranks #872 by composite RQD confidence (29/100, grade E) and #387 by equity capitalization ($786.5M). Within this direct 5-issuer industry benchmark cohort, COLL leads on earnings valuation at 12.4x trailing P/E, while COLL leads on capital efficiency and profitability with 85.0% ROIC and 59.3% gross margin. COLL currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with AVBP at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AVBP
ACTIVE
ArriVent BioPharma Inc. | E | 29/100 | — | — | -35.0% | -6.77% | $786.5M | Benchmark Subject |
| HELP Helus Pharma Inc. | D+ | 54/100 | — | — | — | -1.07% | $782.5M | /help-vs-avbp → |
| COLL Collegium Pharmaceutical Inc. | C- | 59/100 | 12.4x | 59.3% | 85.0% | -0.96% | $782.3M | /coll-vs-avbp → |
| ARDX Ardelyx Inc. | E | 24/100 | — | 90.3% | -32.7% | -2.26% | $772.5M | /ardx-vs-avbp → |
| ANNX Annexon Inc. | E | 30/100 | — | — | -35.0% | +1.00% | $760.2M | /annx-vs-avbp → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), ArriVent BioPharma Inc. (AVBP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$166.3M, operating cash flow of -$160.6M, and free cash flow of -$160.6M (-128.7% YoY). On the balance sheet, AVBP closed FY2025 with $333.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$166.3M | -$160.6M | -$160.6M | $333.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$80.5M | -$70.2M | -$70.2M | $274.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$69.3M | -$55.8M | -$55.8M | — | — |
As of 2026-11-02, ArriVent BioPharma Inc. (NASDAQ: AVBP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $14.87 (-6.77% 1D, market cap $786.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AVBP ranks #872 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AVBP carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HELP (Helus Pharma Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $782.5M) and COLL (Collegium Pharmaceutical Inc.) posts a C- grade (59/100 RQD, P/E 12.4x, ROIC 85.0%, cap $782.3M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
Per AVBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001868279), ArriVent BioPharma Inc. generated $0 in revenue, -$166.3M in net income, and -$160.6M in free cash flow against $333.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
AVBP last traded at $14.87 (-6.77% on volume of 1,194,913 shares), positioning the stock -39.28% below its 50-day simple moving average ($24.49) and -44.78% below its 200-day simple moving average ($26.93). Across its 52-week range of $11.36 to $35.83, AVBP sits at the 14.3% percentile with a 14-day RSI of 36.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.01 to $16.73).
Why AVBP Stock dropped -6.77% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
The Roarable RQD assigns AVBP a score of 29 out of 100, a letter grade of E, and a verdict of "Roarable Strong Sell — Forensic Risk / Avoid." Across its five pillars, the fundamental cash engine scores 6/20 (ROIC of -35% and FCF yield of -20.42%), indicating that the company is consuming rather than generating cash relative to its market value. Whale 13F flow scores 3/20 and insider conviction scores 3/20, per the Roarable RQD rating, signaling weak institutional and insider support in the source data. Macro regime fit scores 7/20 with a beta of 1.0, meaning the stock's sensitivity to the broader market is average, but the sector-sensitivity component still weighs against it. Forensic balance sheet scores 10/20, reflecting an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a debt-to-equity ratio of 0.5. For a prospective investor, the practical implication is that upside would have to come from clinical or regulatory outcomes not captured in these cash and balance-sheet metrics, while valuation support from current cash generation is negative. This is an analytical reading of the rating, not personalized advice.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-177.5M | $-166.3M | N/A | $-160.6M | $45.5M | N/A |
| FY 2024 | $0.0M | $-94.3M | $-80.5M | N/A | $-70.2M | $74.3M | N/A |
| FY 2023 | $0.0M | $-74.6M | $-69.3M | N/A | $-55.8M | N/A | N/A |
Per the SEC financials, AVBP reported zero revenue across all three periods, with operating losses widening from $-74.6M (FY 2023) to $-177.5M (FY 2025). Gross, operating, and net margins are each reported as 0% in the market data, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, per the Roarable RQD rating, with a debt-to-equity ratio of 0.5. Cash declined from $74.3M in FY 2024 to $45.5M in FY 2025 per the SEC financials.
The news wire contains six items, all dated within the last 15 hours of the data timestamp. Three are tagged RISK WATCH and tied to trial outcomes: a Fierce Biotech report describes a phase 3 lung cancer trial as failing, an Investing.com report describes a 60% stock decline after a trial missed its primary endpoint, and a TradingView report describes a 12-month price target cut to $37.55, implying 32% upside. A Seeking Alpha item similarly attributes a plunge to a cancer trial failure. A Benzinga item asks why the stock is tumbling, and a Yahoo Finance Singapore item is a general market-action piece. The butterfly supply-chain graph reports no supply-chain links and no proprietary signals. The clinical-trial failure is the dominant catalyst in the source data, though the exact trial details are Not available in source data beyond the headlines.
Real-time company headlines, analyst actions, and sector developments for ArriVent BioPharma Inc. (AVBP) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Singapore report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
TradingView report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
Fierce Biotech report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
Morningstar report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering ArriVent BioPharma Inc. (AVBP) market action, institutional positioning, and fundamental catalysts.
Welcome to the AVBP (ArriVent BioPharma Inc.) Roar Pit. Current RQD Composite is 29/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on AVBP, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless ArriVent BioPharma Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on AVBP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $15.95 (52-wk range $11.36 - $35.83), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).